SG Americas Securities LLC decreased its position in shares of Solventum Co. (NYSE:SOLV - Free Report) by 24.1% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 19,183 shares of the company's stock after selling 6,100 shares during the quarter. SG Americas Securities LLC's holdings in Solventum were worth $1,267,000 as of its most recent SEC filing.
A number of other institutional investors have also recently bought and sold shares of the company. MML Investors Services LLC raised its position in shares of Solventum by 3.2% during the third quarter. MML Investors Services LLC now owns 5,345 shares of the company's stock worth $373,000 after purchasing an additional 168 shares during the period. Tokio Marine Asset Management Co. Ltd. lifted its stake in Solventum by 4.2% in the third quarter. Tokio Marine Asset Management Co. Ltd. now owns 4,966 shares of the company's stock valued at $346,000 after buying an additional 200 shares in the last quarter. IVC Wealth Advisors LLC boosted its holdings in shares of Solventum by 5.0% in the third quarter. IVC Wealth Advisors LLC now owns 6,649 shares of the company's stock valued at $464,000 after buying an additional 318 shares during the period. KKM Financial LLC increased its position in shares of Solventum by 7.9% during the third quarter. KKM Financial LLC now owns 4,367 shares of the company's stock worth $304,000 after acquiring an additional 319 shares in the last quarter. Finally, Global Trust Asset Management LLC raised its holdings in shares of Solventum by 137.5% during the fourth quarter. Global Trust Asset Management LLC now owns 570 shares of the company's stock worth $38,000 after acquiring an additional 330 shares during the period.
Wall Street Analysts Forecast Growth
A number of equities analysts have issued reports on the company. Piper Sandler increased their target price on Solventum from $71.00 to $75.00 and gave the stock a "neutral" rating in a report on Friday, November 8th. Mizuho began coverage on Solventum in a research report on Wednesday, December 4th. They issued a "neutral" rating and a $70.00 target price on the stock. Stifel Nicolaus started coverage on Solventum in a research note on Tuesday, October 8th. They issued a "buy" rating and a $82.00 target price on the stock. Finally, Morgan Stanley raised their price target on shares of Solventum from $60.00 to $73.00 and gave the stock an "equal weight" rating in a research note on Monday, November 11th. One investment analyst has rated the stock with a sell rating, nine have given a hold rating and one has given a buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of "Hold" and a consensus target price of $68.29.
Check Out Our Latest Research Report on SOLV
Solventum Stock Down 1.6 %
Shares of NYSE:SOLV traded down $1.19 during midday trading on Friday, hitting $74.11. The stock had a trading volume of 659,582 shares, compared to its average volume of 993,247. Solventum Co. has a 12 month low of $47.16 and a 12 month high of $96.05. The business's 50-day simple moving average is $70.11 and its 200-day simple moving average is $67.03. The company has a debt-to-equity ratio of 2.45, a current ratio of 1.15 and a quick ratio of 0.83.
Solventum (NYSE:SOLV - Get Free Report) last released its quarterly earnings data on Thursday, November 7th. The company reported $1.15 earnings per share for the quarter, missing the consensus estimate of $1.38 by ($0.23). The firm had revenue of $2.08 billion for the quarter, compared to the consensus estimate of $2.05 billion. As a group, research analysts predict that Solventum Co. will post 6.58 EPS for the current fiscal year.
About Solventum
(
Free Report)
Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.
Read More
Before you consider Solventum, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Solventum wasn't on the list.
While Solventum currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
